Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
HRMY or RGEN: Which Is the Better Value Stock Right Now?
12:40pm, Tuesday, 14'th Jan 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two co
Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 07'th Jan 2025
WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i
Repligen Launches the CTech™ SoloVPE® PLUS System
07:30am, Monday, 06'th Jan 2025
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of i
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
08:11am, Monday, 16'th Dec 2024
BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 12'th Dec 2024
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
07:30am, Thursday, 12'th Dec 2024
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
07:30am, Monday, 09'th Dec 2024
Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript
03:07pm, Tuesday, 12'th Nov 2024
Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
02:40pm, Tuesday, 12'th Nov 2024
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth
01:19pm, Tuesday, 12'th Nov 2024
Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
10:05am, Tuesday, 12'th Nov 2024
Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago.
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects
06:36am, Tuesday, 12'th Nov 2024
Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though inte
Repligen Corporation to Present at Upcoming Investor Conferences
07:30am, Tuesday, 05'th Nov 2024
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
11:05am, Tuesday, 22'nd Oct 2024
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics
